In November, 2012 IBI received FDA approval of its Orphan Drug Designation for IBI-80090 (mephalan for intraocular injection) for the treatment of retinoblastoma. IBI will be collaborating with Memorial Sloan Kettering Cancer Center on this project.
For Additional Information Contact:
David S. Tierney, M.D.
Chief Executive Officer
1253 Reamwood Avenue
Sunnyvale, California 94089
Icon Bioscience, Inc. | 1253 Reamwood Ave. | Sunnyvale, CA | 94089 | 650-369-4049